Bluejay Diagnostics Inc Total Liabilities
Bluejay Diagnostics Inc total liabilities. Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has total liabilities worth $1.42 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Bluejay Diagnostics Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Bluejay Diagnostics Inc (2019–2025)
Total liabilities of Bluejay Diagnostics Inc from 2019 to 2025. This chart illustrates how Bluejay Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data.
Bluejay Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Bluejay Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
France Tourisme Immobilier SA
PA:MLFTI
|
France | €6.94 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA3.73 Million |
|
Redcentric
LSE:RCN
|
UK | GBX125.64 Million |
|
Northern Venture Trust
LSE:NVT
|
UK | GBX208.00K |
|
Propell Holdings Ltd
AU:PHL
|
Australia | AU$13.84 Million |
|
Tullow Oil PLC
LSE:TLW
|
UK | GBX3.53 Billion |
|
ZAZZ Energy of Sweden AB
ST:ZAZZ-B
|
Sweden | Skr73.68 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Bluejay Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bluejay Diagnostics Inc assets under control.
Liquidity & Leverage Metrics
Bluejay Diagnostics Inc Total Liabilities Ratios Explained
Bluejay Diagnostics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bluejay Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual total liabilities of Bluejay Diagnostics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.14 Million | +23.28% |
| 2024-12-31 | $927.92K | -52.99% |
| 2023-12-31 | $1.97 Million | -0.32% |
| 2022-12-31 | $1.98 Million | +210.75% |
| 2021-12-31 | $637.16K | -88.87% |
| 2020-12-31 | $5.72 Million | +48.70% |
| 2019-12-31 | $3.85 Million | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more